h1

h2

h3

h4

h5
h6

001     1004812
005     20251006102124.0
024 7 _ |2 ISSN
|a 2059-3635
024 7 _ |2 ISSN
|a 2095-9907
024 7 _ |2 SCOPUS
|a SCOPUS:2-s2.0-85217357326
024 7 _ |2 WOS
|a WOS:001411308000001
024 7 _ |2 datacite_doi
|a 10.18154/RWTH-2025-01640
024 7 _ |2 doi
|a 10.1038/s41392-025-02131-z
024 7 _ |2 pmid
|a pmid:39885144
037 _ _ |a RWTH-2025-01640
041 _ _ |a English
082 _ _ |a 610
100 1 _ |0 P:(DE-588)1354280644
|a Koch, Lars Leonard
|b 0
|u rwth
245 _ _ |a Artesunate: attenuating TLR4/MD2 signaling to alleviate cardiac fibrosis
|h online, print
260 _ _ |a London
|b Macmillan Publishers, part of Springer Nature
|c 2025
300 _ _ |a 1-2
336 7 _ |0 0
|2 EndNote
|a Journal Article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
536 _ _ |0 G:(DE-82)021000-OAPKF
|a OAPKF - Open-Access-Publikation mit Unterstützung der RWTH Aachen University (021000-OAPKF)
|c 021000-OAPKF
|x 0
536 _ _ |0 G:(GEPRIS)322900939
|a DFG project G:(GEPRIS)322900939 - TRR 219: Mechanismen kardiovaskulärer Komplikationen bei chronischer Niereninsuffizienz (322900939)
|c 322900939
|x 1
536 _ _ |0 G:(GEPRIS)417911533
|a DFG project G:(GEPRIS)417911533 - KFO 344: Mechanismen und molekulare Zielstrukturen der Myelofibrose in Myeloproliferativen Neoplasien (MPN) (417911533)
|c 417911533
|x 2
536 _ _ |0 G:(GEPRIS)445703531
|a DFG project G:(GEPRIS)445703531 - KFO 5011: Integration neuer Methoden zur Verbesserung von translationaler Nierenforschung (445703531)
|c 445703531
|x 3
536 _ _ |0 G:(EU-Grant)101043403
|a TargetCKD - Identification of novel diagnostic, predictive and therapeutic strategies in chronic kidney disease (101043403)
|c 101043403
|f ERC-2021-COG
|x 4
536 _ _ |0 G:(BMBF)01ZX1914A
|a BMBF 01ZX1914A - Fibromap - Erstellung einer dreidimensionalen Karte fibrotischen Gewebes - klinische, molekularbiologische und bioinformatische Analysen (01ZX1914A)
|c 01ZX1914A
|x 5
536 _ _ |0 G:(BMBF)01EJ2201A
|a BMBF 01EJ2201A - Verbund CureFib - Identifikation und Analyse von Organ-übergreifenden Pathomechanismen fibrotischer Erkrankungen zur Entwicklung neuer Therapeutika - Räumliche und zeitliche Kartierung der Nieren- und der Knochenmarksfibrose und Identifikation von Organ-übergreifenden Zielmolekülen für die Therapie (01EJ2201A)
|c 01EJ2201A
|x 6
536 _ _ |0 G:(BMBF)01KL1907
|a BMBF 01KL1907 - ERA-CVD Verbund: MEND-AGE: Untersuchung von mesenchymal - endothelialer Interaktion, Heterogenität und Funktion während vaskulärer Alterung und Atherosklerose (01KL1907)
|c 01KL1907
|x 7
536 _ _ |0 G:(EU-Grant)101138549
|a FibroTarg - Targeting kidney fibrosis by a novel myofibroblast specific small molecule inhibitor (101138549)
|c 101138549
|f ERC-2023-POC
|x 8
588 _ _ |a Dataset connected to CrossRef, Journals: publications.rwth-aachen.de
591 _ _ |a Germany
591 _ _ |a Netherlands
700 1 _ |0 P:(DE-588)1188531778
|a Hoeft, Konrad
|b 1
|u rwth
700 1 _ |0 P:(DE-588)135824044
|a Kramann, Rafael
|b 2
|e Corresponding author
|u rwth
773 _ _ |0 PERI:(DE-600)2886872-9
|a 10.1038/s41392-025-02131-z
|n 1
|p 46
|t Signal transduction and targeted therapy
|v 10
|x 2059-3635
|y 2025
856 4 _ |u https://publications.rwth-aachen.de/record/1004812/files/1004812.pdf
|y OpenAccess
876 7 _ |c 100
|d 2025-02-20
|e Other
|j DEAL
|v 7.00
|x 021000-932610
|z Servicepauschale
876 7 _ |c 2576.17
|d 2025-02-20
|e APC
|j DEAL
|v 180.33
|x 021000-932610
909 C O |o oai:publications.rwth-aachen.de:1004812
|p openaire
|p open_access
|p openCost
|p ec_fundedresources
|p driver
|p dnbdelivery
|p VDB
|p OpenAPC
910 1 _ |0 I:(DE-588b)36225-6
|6 P:(DE-588)1354280644
|a RWTH Aachen
|b 0
|k RWTH
910 1 _ |0 I:(DE-588b)36225-6
|6 P:(DE-588)1188531778
|a RWTH Aachen
|b 1
|k RWTH
910 1 _ |0 I:(DE-588b)36225-6
|6 P:(DE-588)135824044
|a RWTH Aachen
|b 2
|k RWTH
914 1 _ |y 2025
915 1 _ |0 StatID:(DE-HGF)0031
|2 StatID
|a Peer reviewed article
|x 0
915 _ _ |0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
|a Creative Commons Attribution CC BY 4.0
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:44:53Z
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b SIGNAL TRANSDUCT TAR : 2022
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2024-04-10T15:44:53Z
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2024-04-10T15:44:53Z
915 _ _ |0 StatID:(DE-HGF)0510
|2 StatID
|a OpenAccess
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2024-12-17
915 _ _ |0 StatID:(DE-HGF)9930
|2 StatID
|a IF >= 30
|b SIGNAL TRANSDUCT TAR : 2022
|d 2024-12-17
915 p c |0 PC:(DE-HGF)0000
|2 APC
|a APC keys set
915 p c |0 PC:(DE-HGF)0003
|2 APC
|a DOAJ Journal
915 p c |0 PC:(DE-HGF)0113
|2 APC
|a DEAL: Springer Nature 2020
920 1 _ |0 I:(DE-82)531020-2_20140620
|k 531020-2 ; 932610
|l Klinik und Lehrstuhl für Innere Medizin (mit dem Schwerpunkt Nephrologie und Immunologie)
|x 0
980 1 _ |a FullTexts
980 _ _ |a APC
980 _ _ |a I:(DE-82)531020-2_20140620
980 _ _ |a UNRESTRICTED
980 _ _ |a VDB
980 _ _ |a journal

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21